Showing results (131-140 of 1,343) with videos related to
Sort By:
Pageof 135
The Pharmacogenomics Journal|May 28, 2020
Determinants of stakeholders' intention to adopt pharmacogenomicMuhammad Adzran Che Mustapa, Latifah Amin, Zurina MahadiThe Pharmacogenomics Journal|March 12, 2003
Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenicsD Nikoloff, J C Shim, M Fairchild, et al.The Pharmacogenomics Journal|March 12, 2003
Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patientsM Holthe, T N Rakvåg, P Klepstad, et al.The Pharmacogenomics Journal|March 12, 2003
Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuseE Lehrmann, J Oyler, M P Vawter, et al.The Pharmacogenomics Journal|May 15, 2003
Pharmacoproteomics in drug developmentFrank A Witzmann, Raymond A GrantThe Pharmacogenomics Journal|May 15, 2003
Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphismA Rousseva, C Henry, D van den Bulke, et al.The Pharmacogenomics Journal|May 15, 2003
Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6M Desai, J E Tanus-Santos, L Li, et al.The Pharmacogenomics Journal|June 20, 2003
Pharmacogenomics of human UDP-glucuronosyltransferase enzymesC GuillemetteThe Pharmacogenomics Journal|June 20, 2003
Human dopamine transporter gene variation: effects of protein coding variants V55A and V382A on expression and uptake activitiesZhicheng Lin, George R UhlThe Pharmacogenomics Journal|June 20, 2003
Target validation in hypoxia-induced vascular remodeling using transcriptome/metabolome analysisH Amano, K Maruyama, M Naka, et al.Pageof 135